Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Details Textual)

Note 3 - Revenue (Details Textual) $ / shares in Units, $ in Thousands, € in Millions							1 Months Ended			3 Months Ended		9 Months Ended			12 Months Ended
	May 19, 2021 USD ($)	Apr. 24, 2021 USD ($)	Apr. 01, 2021 USD ($) $ / shares shares	Mar. 24, 2021 USD ($) $ / shares shares	Feb. 08, 2018 USD ($)	May 02, 2017 USD ($)	Aug. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jan. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 EUR (€)	Jan. 01, 2019 USD ($)
Contract with Customer, Liability, Current										$ 18,498		$ 18,498			$ 25,116
Contract with Customer, Liability, Noncurrent										18,484		18,484			38,403
Contract with Customer, Liability, Revenue Recognized										5,300		19,500
Number of Technology Licenses						5
Revenues, Total										5,370	$ 4,057	20,056		$ 22,975
Increase (Decrease) in Contract with Customer, Liability										0		0
Genentech [Member]
Revenue, Remaining Performance Obligation, Variable Consideration Amount	$ 1,400
Number Of Initial Research Programs	2
Number Of Optional Additional Research Programs	2
Revenue from Contract with Customer, Collaboration Fee On Additional Program	$ 10,000
Revenue from Contract with Customer, Agreement Termination Notice Period Within Material Breach (Day)	90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period Before First Commercial Sale (Day)	90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period After First Commercial Sale (Day)	180 days
Number of Research Programs	4
Number of Performance Obligations	2
Revenue, Remaining Performance Obligation, Amount										11,900		11,900
Revenues, Total										553	863	2,733		863
Genentech [Member] \| License and Collaboration Agreement [Member]
Number of Performance Obligations	5
Genentech [Member] \| Platform Technology License [Member]
Number of Performance Obligations	2
Genentech [Member] \| Governance Committee Participation [Member]
Number of Performance Obligations	1
Seattle Genetics Inc. [Member]
Number of Performance Obligations					3
Revenue, Remaining Performance Obligation, Amount										16,100		16,100
Contract with Customer, Liability, Current										10,000		10,000
Contract with Customer, Liability, Noncurrent										3,400		3,400
Amended Collaboration Agreement, Resale of Stock, Period (Day)				60 days
Revenues, Total										155	(280)	3,074		424
Seattle Genetics Inc. [Member] \| Private Placement [Member]
Contract with Customer, Liability, Total				$ 3,300
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares				3,706,174
Sale of Stock, Consideration Received on Transaction				$ 13,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares				$ 3.51
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares				$ 2.61
Seattle Genetics Inc. [Member] \| License and Collaboration Agreement [Member]
Number of Research Programs				3	3
Number of Performance Obligations					6
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)					12 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)					90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)					180 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)					90 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)					90 days
Number Of Licenses					3
Number Of Swap Options					2
Seattle Genetics Inc. [Member] \| Platform Technology License [Member]
Number of Performance Obligations					3
Number of Target Programs					3
Seattle Genetics Inc. [Member] \| Governance Committee Participation [Member]
Number of Performance Obligations					1
Seattle Genetics Inc. [Member] \| Other Arrangement [Member]
Number of Research Programs					2
Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Contract with Customer, Liability, Total					$ 1,200,000
Research and Development Arrangement, Contract to Perform for Others, Compensation Earned					$ 4,900
Seattle Genetics Inc. [Member] \| Antibody Target Swap [Member]
Number of Performance Obligations					2
Astra Zeneca A B [Member]
Contract with Customer, Liability, Total										700		700
Research Collaboration Agreement Period (Year)						5 years
Revenue, Remaining Performance Obligation, Amount										6,900		6,900
Contract with Customer, Liability, Current										600		600
Contract with Customer, Liability, Noncurrent										6,300		6,300
Amended Collaboration Agreement, Resale of Stock, Period (Day)			60 days
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation							$ 5,000		$ 4,700
Revenues, Total								$ 13,000		4,404	1,607	9,026		18,309
Number of Discovery Programs Discontinued									1
Capitalized Contract Cost, Amortization										200	200	300		300
Astra Zeneca A B [Member] \| Accounting Standards Update 2014-09 [Member]
Capitalized Contract Cost, Net, Total						$ 1,600				200		200
Capitalized Contract Cost, Gross																		$ 1,100
Astra Zeneca A B [Member] \| Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares			3,584,230
Sale of Stock, Consideration Received on Transaction			$ 10,000
Sale of Stock, Price Per Share (in dollars per share) \| $ / shares			$ 2.79
Sale of Stock, Fair Value, Price Per Share (in dollars per share) \| $ / shares			$ 2.60
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member]
Number of Performance Obligations						16
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)						12 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)						90 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)						180 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)						180 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)						180 days
Number of Novel Proteins						4
Agreement Termination Notice Period Upon Of Breach Of Payment Obligations (Day)						30 days
Remaining Performance Obligation, Estimated Term (Month)						12 months
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Minimum [Member]
Number of Collaboration Products						2
Astra Zeneca A B [Member] \| License and Collaboration Agreement [Member] \| Maximum [Member]
Number of Collaboration Products						4
Number of Programs						2
Number of Research Licenses						4
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						$ 45,000
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Estimated Development And Manufacturing Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						14,200
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Sales Milestone Payments [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						12,500
Astra Zeneca A B [Member] \| Up-front Payment Arrangement [Member] \| Estimated Phase 2a Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						4,700
Astra Zeneca A B [Member] \| Additional Other Research Services [Member]
Revenue from Contract with Customer, Allocable Arrangement Consideration Allocation						$ 4,700
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Number of Performance Obligations																10	10
Revenue, Remaining Performance Obligation, Amount										4,800		4,800
Contract with Customer, Liability, Current										800		800
Contract with Customer, Liability, Noncurrent										3,900		3,900
Contract with Customer, Liability, Revenue Recognized												4,900
Number of Novel Proteins																1	1
Number of Programs																3	3
Revenues, Total										258	$ 1,867	5,223		$ 3,379
Capitalized Contract Cost, Amortization												$ 100
Number of Ongoing Performance Obligations												3	3
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Accounting Standards Update 2014-09 [Member]
Capitalized Contract Cost, Net, Total										0		$ 0						$ 500
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| License and Collaboration Agreement [Member]
Number of Programs																5	5
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax												3,700	€ 3.3
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member] \| Minimum [Member]
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)																90 days	90 days
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Collaborative Arrangement [Member] \| Maximum [Member]
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)																120 days	120 days
License [Member] \| Genentech [Member]
Contract with Customer, Liability, Total	$ 20,000
Contract with Customer, Liability, Current										7,100		7,100
Contract with Customer, Liability, Noncurrent										$ 4,800		$ 4,800
License [Member] \| B P Assets X I I Inc [Member]
Revenue, Remaining Performance Obligation, Amount		$ 6,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		4,000
License [Member] \| B P Assets X I I Inc [Member] \| Exclusive Product License Agreement [Member]
Contract with Customer, Liability, Total		10,000
Revenue, Remaining Performance Obligation, Variable Consideration Amount		352,500
Revenue, Remaining Performance Obligation, Amount		10,000
Revenue from Contract with Customer, Contribution Towards Manufacturing Activities		$ 4,000
Revenue from Contract with Customer, Period After Effective Date Agreements May Be Terminated (Month)		9 months
Revenue from Contract with Customer, Agreement Termination Advance Notice Period (Day)		60 days
Revenue from Contract with Customer, Agreement Termination Advance Notice Period If Marketing Approval Obtained (Day)		120 days
Revenue from Contract with Customer, Agreement Termination Notice Period Upon Material Breach (Day)		180 days
Revenue from Contract with Customer, Agreement Termination Notice Period, Non-Payment Of Undisputed Amounts (Day)		60 days
Revenue from Contract with Customer, Agreement Termination, Additional Notice Period Upon Material Breach (Day)		180 days
Revenue from Contract with Customer, Agreement Obligation Cost		$ 4,000
Contract with Customer, Liability, Revenue Recognized															$ 5,700
License [Member] \| Seattle Genetics Inc. [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax					$ 30,000
License [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] \| Up-front Payment Arrangement [Member]
Revenue from Contract with Customer, Excluding Assessed Tax																$ 32,000	€ 30.0
Research And Development Services [Member] \| Genentech [Member]
Research Collaboration Agreement Period (Year)	3 years
Research And Development Services [Member] \| Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]
Number of Development Programs																2	2
Number of Development Milestones																3	3